Maviret (Glecaprevir, Pibrentasvir)

Glecaprevir blocks the HCV NS3/4A protease, preventing cleavage of the viral polyprotein, while pibrentasvir inhibits the NS5A replication complex, disrupting viral RNA replication and assembly. The combined action halts viral replication, allowing the immune system to clear infected cells.

The prescribed dose of Maviret is determined by the treating physician based on the patient’s clinical profile, genotype, and treatment guidelines. The standard regimen consists of one tablet containing 300 mg glecaprevir and 120 mg pibrentasvir taken orally once daily for the duration recommended by the prescriber.

Safety data for Maviret in pregnant or nursing women are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential benefit justifies the potential risk to the fetus, and breastfeeding decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with other direct‑acting antiviral regimens, Maviret offers a pangenotypic option that combines a protease inhibitor and an NS5A inhibitor in a single tablet, allowing a short, once‑daily course without the need for ribavirin. Efficacy and safety are comparable to other approved regimens, but selection depends on genotype, comorbidities, and drug‑interaction profiles.

Store Maviret tablets at temperatures below 25 °C in the original packaging, protected from moisture and direct sunlight. Do not store in bathrooms or near heat sources. Keep out of reach of children and dispose of any unused tablets according to local regulations.

Maviret is taken orally as a single tablet containing 300 mg glecaprevir and 120 mg pibrentasvir. The tablet should be swallowed whole with water, preferably at the same time each day, and can be taken with or without food, unless otherwise directed by the prescriber.

Serious adverse events reported with Maviret include elevated liver enzymes, hepatic decompensation, severe rash or allergic reactions, and hematologic abnormalities such as anemia or thrombocytopenia. Patients should be monitored regularly for signs of liver dysfunction or hypersensitivity, and treatment should be discontinued if severe reactions occur.

Maviret is contraindicated in patients with severe hepatic impairment (Child‑Pugh class C) and should be avoided in individuals receiving strong CYP3A inducers such as rifampin, carbamazepine, or St. John’s wort. Caution is also advised for patients with moderate hepatic impairment, pregnancy, or breastfeeding, and use should be guided by a qualified healthcare professional.